OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

HTML

Year: 2015
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-15-1338
Authors: John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John S. Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison J. Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey
Institutions: The University of Texas at San Antonio Health Science Center, Dana-Farber Cancer Institute, University of Pennsylvania, Massachusetts General Hospital, Winship Cancer Institute
Language: English

Topic: Ubiquitin and proteasome pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: pevonedistat, MLN4924, NEDD8-activating enzyme inhibitor, dose-limiting toxicity, maximum tolerated dose, hepatotoxicity, hyperbilirubinemia, pharmacokinetics, pharmacodynamics, cullin-RING ligases, Cdt1, Nrf2, advanced solid tumors, dexamethasone
SDG: Good health and well-being

Open Access status: closed

Funders: University of Pennsylvania, National Cancer Institute
Awards: G1211761604, Mays Cancer Center at UT Health SA
OpenAlex ID: W2184335538
FWCI: 4.166
Cites: 42
Cited by: 177
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security